CYP2D6 polymorphism is not crucial for the disposition of selegiline

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 4, 1998, Pages 402-411

  Scheinin, Harry ^a   Anttila, Markku ^b   Dahl, Marja Liisa ^b   Karnani, Hari ^b   Nyman, Leena ^b   Taavitsainen, Päivi ^b   Pelkonen, Olavi ^b   Bertilsson, Leif ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CYTOCHROME P450; DEBRISOQUINE; DESMETHYLSELEGILINE; DEXTROMETHORPHAN; DRUG METABOLITE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENETIC POLYMORPHISM; HEADACHE; HUMAN; INSOMNIA; LIVER MICROSOME; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL;

ADRENERGIC AGENTS; ADULT; AMPHETAMINES; AREA UNDER CURVE; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; FEMALE; HUMANS; MALE; METHAMPHETAMINE; MICROSOMES, LIVER; MONOAMINE OXIDASE INHIBITORS; POLYMORPHISM, GENETIC; REFERENCE VALUES; SELEGILINE;

EID: 0031707435     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90071-6     Document Type: Article

References (35)

1. Knoll J. The possible mechanism of action of (-)-deprenyl in Parkinson's disease. J Neural Transm 1978;43:177-98.
2. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245:519-22.
3. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-71.
4. Heinonen EH, Rinne UK. Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand 1989;80:103-11.
5. Riederer P, Youdim MBH. Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with 1-deprenyl. J Neurochem 1986;46:1359-65.
6. 11C-labeled suicide inactivators and PET. Science 1987;235:481-5.
7. Yoshida T, Yamada Y, Yamamoto T, Kuroiwa Y. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 1986;16:129-36.
8. Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 1997;25:657-62.
9. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline: an update. Clin Pharmacokinet 1997;33:91-102.
10. Grace JM, Kinter MT, MacDonald TL. Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,-dimethyl-N-propylphenethylamine, by cytochrome P450 2D6. Chem Res Toxicol 1994;7:286-90.
11. Bertilsson L, Ya-Qing L, Yun-Long D, Yin L, Tang-Yun K, Xia-Mau L, et al. Pronounced difference between native chinese and swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
12. Sanz EJ, Villén T, Alm C, Bertilsson L. S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989;45:495-9.
13. Heim MA, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
14. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-20.
15. Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykkö K, Vuorinen J, et al. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 1989;27:243-55.
16. Pelkonen O, Kaltiala EH, Larmi TKI, Kärki NT. Cytochrome P-450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes. Chem Res Toxicol 1974;3:566-73.
17. Kronbach T, Mathys D, Gut J, Catin T, Meyer UA. Highperformance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 1987;162:24-32.
18. Park YH, Kullberg MP, Hinsvark ON. Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. J Pharm Sci 1984;73:24-9.
19. Mahgoub A, Idle JR, DRing LG. Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
20. Alván G, Bechtel P, Iselius L, Gundert-Remy U. The hydroxylation polymorphism of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
21. Bertilsson L, Dahl ML. Polymorphic drug oxidation: relevance of the treatment of psychiatric disorders. CNS Drugs 1996;5:200-23.
22. Heinonen EH, Anttila MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykkö KA, et al. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. J Clin Pharmacol 1997;37:602-9.
23. Law MYL, Moody DE. Urinary excretion of amphetamine and 4′-hydroxyamphetamine by sprague dawley and dark agouti rats. Life Sci 1994;54:1073-9.
24. Heinonen, EH, Anttila MI, Lammintausta RAS. Pharmacokinetic aspects of 1-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 1994;56:742-9.
25. Elsworth JD, Sandler M, Lees AJ, Ward C, Stern GM. The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties. J Neural Transm 1982;54:105-10.
26. Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry 1997;9:7-13.
27. Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R, Mäki-Ikola O, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 1997;20:419-33.
28. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam, but not of clonazepam. Clin Pharmacol Ther 1992;52:479-86.
29. Sindrup SH, Brøsen K, Hansen MGL. Pharmacokinetics of citalopram in relation to the spartein and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11-7.
30. Balant LP, Gundert-Remy U, Boobis AR, von Bahr C. Relevance of genetic polymorphism in drug metabolism in the development of new drugs. Eur J Clin Pharmacol 1989;36:551-4.
31. Bertilsson L, Åberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985;7:478-80.
32. Heinonen EH, Anttila M, Karnani H, Lammintausta R. Pharmacokinetics of selegiline after oral dosing [abstract]. Mov Disord 1994;9:57.
33. Poirier J, Roy M, Campanella G, Cloutier T, Paris S. Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs [letter]. Lancet 1987;2:386.
34. Kurth MC, Kurth JH. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinsons' disease. Am J Med Genet 1993;48:166-8.
35. Agúndez JAG, Jiménez-Jiménez FJ, Luengo A, Bernai ML, Molina JA, Ayuso L, et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995;57:291-8.